Affimed raises $14 million from J&J through innovative deal
This article was originally published in Scrip
Affimed Therapeutics and Johnson & Johnson have entered a collaboration under a novel deal structure that sees Affimed receive cash for an early-stage discovery program, while J&J gets to fund research directly from its balance sheet, a major tax advantage.
You may also be interested in...
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.